Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 174 of 5804
-
Double attack: pill and radiation take on lung cancer
Disease control OngoingThis study evaluates the combination of two well-tolerated therapies, osimertinib and Stereotactic Ablative Radiation (SABR).
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Immunotherapy combo shows promise in advanced cervical cancer trial
Disease control CompletedThe study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will …
Phase: PHASE3 • Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hair loss drug shows promise in major trial
Disease control CompletedThis study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the ope…
Phase: PHASE2, PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy shows promise for deadly IPF Flare-Ups
Disease control CompletedAcute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to …
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a JAK inhibitor improve stem cell transplant success in myelofibrosis?
Disease control CompletedThis research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy drug keytruda takes on mysterious cancers of unknown origin
Disease control CompletedAbbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial Type: Single arm phase 2 Type of control: Not applicab…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for kids with relapsed AML: targeted drug combo trial opens
Disease control OngoingQuizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New blood test could replace painful heart biopsies for transplant patients
Diagnosis CompletedHeart transplantation is a life saving therapy for people with end stage heart failure. Acute rejection, a process where the immune system recognizes the transplanted heart as foreign and mounts a response against it, remains a clinical problem despite improvements in immunosuppr…
Sponsor: University of British Columbia • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Could a daily aspirin keep colon cancer from returning?
Disease control OngoingFour retrospective studies were recently published on efficacy of aspirin in patients with surgically resected colon cancer. Two of these studies strongly suggested that aspirin used in low doses (100 mg/d) after surgical resection of colorectal cancer with PI3K mutation could ac…
Phase: PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may inte…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New antibody drug shows promise for Hard-to-Treat lymphoma
Disease control OngoingThe purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): * The dose schedule for epcoritamab * The side effects seen with epc…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could immune activators revive treatment for Hard-to-Treat breast cancer?
Disease control OngoingThis research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelb…
Phase: PHASE2 • Sponsor: Adrienne G. Waks • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: targeted drug shows promise
Disease control CompletedMultiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies. Participants with relapsed/refractory multiple myeloma (RRMM) will be included in this study, to evaluate the efficacy and safety of bela…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 26, 2026 13:16 UTC
-
Could a diabetes injection help early Parkinson's patients?
Disease control CompletedThe main objective of the study is to evaluate the effect of lixisenatide (20 μg/d), versus placebo, administered as add-on therapy with the usual antiparkinsonian treatment, on the progression of motor disability in patients with early PD in order to assess its potential "diseas…
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug shows promise for rare childhood liver disease
Disease control CompletedDouble blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.
Phase: PHASE3 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Immunotherapy combo shows promise in lung cancer before surgery
Disease control CompletedThis is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, I…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThe purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
Phase: PHASE2, PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immunotherapy combo aims to boost hodgkin lymphoma response in slow responders
Disease control OngoingThis study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to stall lung cancer
Disease control CompletedThis is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care \[SoC\] CRT) in patients with locally advanced, unresecta…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New pill hopes to tame Crohn's Flare-Ups Long-Term
Disease control OngoingA multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC